Drugs / Boserolimab
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03396445 | Feb 2018 → Sep 2024 | non-small cell lung carcinoma, triple-negative breast carcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04165070 | Dec 2019 → Feb 2032 expected | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06829199 | Mar 2025 → Jan 2029 | triple-negative breast carcinoma | Merck Sharp & Dohme LLC | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04924101 | Jul 2021 → Jun 2025 | small cell lung carcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT04165096 | Jan 2020 → Apr 2025 | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Boserolimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04924101 ↗ |
| Known as | MK-5890 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095364 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5095364 ↗ |
| Route | Intravenous | “IV infusion” NCT03396445 ↗ |